Menorrhalgia Market
Number of pages: 100 | Report Format: PDF | Published date: February 16, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 19.23 billion |
|
Revenue forecast in 2030 |
US$ 31.14 billion |
|
CAGR |
5.5% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Therapeutics, Route of Administration, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global menorrhalgia market was valued at US$ 19.23 billion in 2021 and is expected to register a revenue CAGR of 5.5% to reach US$ 31.14 billion by 2030.
Menorrhalgia Market Fundamentals
Menorrhalgia is a medical condition characterized by heavy and prolonged menstrual bleeding. It is a common condition that affects many women and has a significant impact on a woman’s quality of life. Symptoms of menorrhalgia include heavy menstrual bleeding, unbearable period pain, and bleeding between periods. The causes of menorrhalgia can be complex and may include hormonal imbalances, structural abnormalities in the uterus, and certain medical conditions. Women across the globe have iron deficiency during their reproductive years due to menstruation, pregnancy, childbirth, and lactation. The most common cause of iron deficiency in women is excessive menstrual bleeding, which is also referred to as menorrhalgia. Severe blood loss results in chronic anemia and pain among adolescent girls and premenopausal women.
There are several types of menorrhalgia, each with different causes and treatments. Primary menorrhalgia is not caused by any underlying medical condition. It is often related to hormonal imbalances and can be treated with hormonal medications, such as birth control pills. Secondary menorrhalgia is caused by an underlying medical condition, such as fibroids, polyps, or thyroid disorders. Treatment involves addressing the underlying condition as well as medications to control bleeding. Functional menorrhalgia is caused by abnormal changes in the lining of the uterus and can be treated with medications, such as tranexamic acid, nonsteroidal anti-inflammatory drugs (NSAIDs), and hormonal medications. Menorrhalgia due to structural abnormality is caused by structural abnormalities, such as uterine fibroids, adenomyosis, endometriosis, and congenital malformations. Treatment involves surgeries to remove abnormal growths.
[6575675]
Menorrhalgia Market Dynamics
Some of the driving factors of the menorrhalgia market include the rising awareness about menorrhalgia, an increase in the number of women in the reproductive age group, rise in the number of cases of endometriosis, adenomyosis, and fibroids, improved healthcare expenditure and government support for the development of new treatments for menorrhalgia. The increasing number of women in the workforce and the growing awareness of the impact of heavy menstrual bleeding on daily life are driving the demand for more convenient and effective treatment options. An increasing number of women suffering from obesity, diabetes, and hypertension is expected to lead to rise in the cases of menorrhalgia.
However, the stigma associated with discussing menstrual-related issues can discourage women from seeking treatment. Taboo or embarrassment surrounding the topic of menstruation can prevent women from talking openly about their menstrual symptoms or seeking help. Lack of access to menstrual products and sanitary facilities can be a barrier to managing menstrual symptoms and can perpetuate shame and embarrassment. Limited access to healthcare in certain regions, particularly in low-income and rural areas, and the high cost of some treatment options, which may not be covered by insurance, are likely to hinder revenue growth in the global market to some extent.
Menorrhalgia Market Ecosystem
The global menorrhalgia market has been analyzed from four perspectives: therapeutics, route of administration, distribution channel, and region.
Menorrhalgia Market by Therapeutics
[7546744]
Based on therapeutics, the global market for menorrhalgia is segmented into hormonal agents and non-hormonal agents.
Non-hormonal therapeutics include NSAIDs and antifibrinolytics. Hormonal agents include long-acting progestogens, ethinylestradiol, and norethisterone. Among these, the non-hormonal agents segment accounted for the large revenue share of the market in 2021. Companies have moved their attention to the development of targeted therapeutics in order to address the growing demand for the treatment of menorrhalgia. A rise in the prevalence of heavy menstrual bleeding and more awareness of the condition may help to raise the market size in the upcoming years, along with anticipated launches of possible therapies.
Menorrhalgia Market by Route of Administration
Based on the route of administration, the global market for menorrhalgia is segmented into oral, vaginal, transdermal, intrauterine, and others.
The oral segment accounted for the largest revenue share of the market in 2021. Oral medications are taken by mouth, typically in the form of pills or tablets. Examples include birth control pills and NSAIDs. Vaginal medications are inserted into the vagina, typically in the form of a cream or gel. Transdermal medications are applied to the skin, typically in the form of a patch. Intrauterine medications are inserted into the uterus in the form of a hormone-releasing intrauterine device (IUD). Oral contraceptives help in menstrual cycle regulation and lessen excessive or prolonged menstrual bleeding. Additionally, pap tests, ultrasound, biopsies, blood tests, and pap smears can all be used to identify menorrhagia.
Menorrhalgia Market by Distribution Channel
In terms of distribution channel, the global market for menorrhalgia is segmented into online pharmacies, retail pharmacies, and hospital pharmacies.
The hospital pharmacies segment accounted for the largest revenue share of the market in 2021. These drugs are typically prescribed by obstetricians and gynecologists in the hospital and clinical settings and are available in both brand name and generic forms.
Menorrhalgia Market by Region
Geographically, the global menorrhalgia market has been segmented into North America, Europe, Asia Pacific, and the rest of the world.
The menorrhalgia market in North America accounted for the largest revenue share in 2021. It has been noted that the U.S. has a high incidence of uterine cancer due to an increase in post-menopausal women population and an increase in the prevalence of obesity in the country. The menorrhalgia market in North America is also driven by factors such as a large patient population, the availability of advanced treatment options, and a strong healthcare system in the region. In addition, a growing awareness about the condition and increasing government initiatives to improve access to healthcare are also driving the market revenue growth in this region.
In Europe, the menorrhalgia market is driven by the availability of advanced treatment options and a strong healthcare system. The market in this region is also expected to grow due to the rising prevalence of the condition, particularly among women of reproductive age.
In Asia Pacific, the menorrhalgia market is driven by factors such as the large population, increase in awareness about the condition, and the advanced healthcare infrastructure in countries such as China and India.
In Latin America, the menorrhalgia market is driven by the increasing prevalence of the condition and the growing awareness about the condition in countries such as Brazil and Mexico.
Menorrhalgia Market Competitive Landscape
The most prominent companies in the global menorrhalgia market are:
Menorrhalgia Market Strategic Developments
Menorrhalgia is a medical condition characterized by heavy and prolonged menstrual bleeding. It is a common condition that affects many women, and it can have a significant impact on a woman’s quality of life.
Torrent Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd, Beximco Pharmaceuticals Ltd., Zydus Cadila, and Novartis AG are among the top market players.
The stigma associated with discussing menstruation-related issues can discourage women from seeking treatment. Taboo or embarrassment surrounding the topic of menstruation can prevent women from talking openly about their menstrual symptoms or seeking help. Lack of access to menstrual products and sanitary facilities can be a barrier to managing menstrual symptoms and perpetuate shame and embarrassment.
The global menorrhalgia market is expected to register a revenue CAGR of 5.5% during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain